Protalix BioTherapeutics Future Growth

Future criteria checks 5/6

Protalix BioTherapeutics is forecast to grow earnings and revenue by 118.3% and 58.9% per annum respectively while EPS is expected to grow by 118.1% per annum.

Key information

118.3%

Earnings growth rate

118.1%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	58.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22

Recent updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Jan 14

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Dec 10

Earnings and Revenue Growth Forecasts

NYSEAM:PLX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	167	100	N/A	N/A	1
12/31/2025	101	55	N/A	N/A	1
12/31/2024	53	2	N/A	N/A	1
9/30/2024	46	-10	7	8	N/A
6/30/2024	38	-15	-4	-3	N/A
3/31/2024	60	7	4	6	N/A
12/31/2023	65	8	-2	-1	N/A
9/30/2023	64	11	-9	-8	N/A
6/30/2023	67	9	-11	-10	N/A
3/31/2023	41	-16	-23	-22	N/A
12/31/2022	48	-15	-26	-25	N/A
9/30/2022	48	-18	-28	-27	N/A
6/30/2022	45	-18	-21	-20	N/A
3/31/2022	43	-24	-8	-6	N/A
12/31/2021	38	-28	-12	-10	N/A
9/30/2021	49	-21	-14	-13	N/A
6/30/2021	48	-21	-16	-14	N/A
3/31/2021	53	-14	-30	-29	N/A
12/31/2020	63	-7	-27	-26	N/A
9/30/2020	61	-7	-23	-22	N/A
6/30/2020	65	-6	-23	-22	N/A
3/31/2020	66	-9	-20	-19	N/A
12/31/2019	55	-18	-20	-19	N/A
9/30/2019	47	-24	-20	-20	N/A
6/30/2019	45	-26	-3	-3	N/A
3/31/2019	38	-26	-6	-6	N/A
12/31/2018	34	-26	-8	-8	N/A
9/30/2018	28	-34	13	14	N/A
6/30/2018	23	-40	N/A	-10	N/A
3/31/2018	25	-32	N/A	-11	N/A
12/31/2017	21	-83	N/A	-10	N/A
9/30/2017	19	-73	N/A	-35	N/A
6/30/2017	16	-69	N/A	-28	N/A
3/31/2017	11	-80	N/A	-31	N/A
12/31/2016	9	-29	N/A	-32	N/A
9/30/2016	7	-35	N/A	-29	N/A
6/30/2016	4	-34	N/A	-34	N/A
3/31/2016	3	-29	N/A	-27	N/A
12/31/2015	4	-27	N/A	-24	N/A
9/30/2015	-6	-31	N/A	-25	N/A
6/30/2015	-4	-33	N/A	-26	N/A
3/31/2015	-2	-32	N/A	-27	N/A
12/31/2014	4	-33	N/A	-29	N/A
9/30/2014	15	-32	N/A	-29	N/A
6/30/2014	15	-30	N/A	-28	N/A
3/31/2014	15	-31	N/A	-29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PLX is expected to become profitable in the next 3 years.

Revenue vs Market: PLX's revenue (58.9% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: PLX's revenue (58.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time

Protalix BioTherapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 20%

Price target decreased to US$9.00

Forecast breakeven pushed back to 2022

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Price target lowered to US$9.75

Recent updates

Protalix BioTherapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Protalix BioTherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Protalix BioTherapeutics, Inc.(NYSEAM:PLX) dropped from Russell Small Cap Comp Value Index

Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus revenue estimates increase by 20%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$9.00

President recently bought US$102k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Forecast breakeven pushed back to 2022

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.91

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.17

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

New 90-day high: US$3.96

Third quarter earnings released

Third-quarter earnings released: Earnings miss expectations

New 90-day low: US$3.35

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

New 90-day low - US$3.37

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

Price target lowered to US$9.75

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies